Penumbra Q2 revenue $390M (+14.9% YoY); net income $34.8M; pending BSX acquisition

Penumbra Inc

Revenue $390.0M, up 14.9% YoY; global thrombectomy $259.0M (+12.5%), embolization & access $131.1M (+20.0%).
Gross profit margin 67.9%, up 1.9 percentage points YoY.
Income from operations $41.0M; net income $34.8M.
Operating expenses include $6.9M acquisition-related costs for pending Boston Scientific acquisition.
Company will not provide FY2026 guidance due to pending acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.